ERNA

Ernexa Therapeutics Inc. (ERNA) | Rumor.io

Ernexa Therapeutics

ERNA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,307

Bullish sentiment (50-day avg)77%

Price to earnings ratio0.01

Market capitalization4M

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-14.1M

Social

What share of all stock conversation is about ERNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

Ernexa Therapeutics reports positive preclinical data for ERNA-201, reinforcing its iMSC platform and accelerating oncology strategy.
The company has paused additional preclinical development expenditures on ERNA-201, preserving the program while concentrating on ERNA-101 and expanding its oncology pipeline.
ERNA-201 results provide a foundation for potential future advancement, and the company believes the data demonstrate proof-of-concept, making it a priority for future development.

Generated by AI

Sentiment

Of the messages about ERNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	54.55% -38.79	90.04% +7.12
Bearish	—	—	45.45% +38.79	9.96% -7.12

Bullish· Jul 15

ERNA-101 has shown complete tumor clearance and durable survival in ovarian cancer models, a significant development ahead of its planned clinical entry.
The stock has a low float of 668K, which can lead to rapid price movements.
The company's potential to easily 100x its current value has been highlighted, indicating a high potential for growth.

Bearish· Jul 15

The company's ovarian cancer treatment results were promising, but the stock has a history of fading after gap-up days, which may lead to a decline.
The stock has been a short signal since the market open, and shorts are likely to continue attacking the company.
The stock's price has been declining, and many investors are expecting it to drop below $8, with some even calling it a "bag trap".

Generated by AI

Topics

Of the messages about ERNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	2.03%
Technical Analysis	—	—	0%	1.92%
Analysts	—	—	0%	1.84%
Controversies	—	—	0%	0.01%
Earnings	—	—	0%	0.02%
Macro	—	—	0%	94.18%

Announcements· Oct 29

Eterna Therapeutics Inc. (ERNA) has partnered with Cellipont Bioservices to advance ERNA-101, an allogeneic iMSC-based cell therapy for ovarian cancer, into clinical manufacturing.
The collaboration will support current Good Manufacturing Practice (cGMP) process development and process scale-up for ERNA-101, which is designed as an off-the-shelf treatment for ovarian cancer.
ERNA-101 has shown potential in reprogramming "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth.

Technical Analysis· Oct 29

The $ERNA stock price is expected to break out above $2.40, with a potential target of $3 or higher if it can close above $2.50.
The stock has a support level at $1.76 and a resistance level at $2.38, with a potential target of $2.57 if it can close above $1.76.
The stock has a strong gap up above the 100-day EMA, with high volume, and is expected to consolidate and possibly flag above the $1.75 area.

Generated by AI

Community

Of the messages about ERNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.9%	7.16%
Newcomers	—	—	88.1%	92.84%

May 7

Newcomers are excited about ERNA's potential due to its strong preclinical survival data and ovarian cancer treatment candidate status, with some comparing it to multibaggers.
There is a high-volatility microfloat setup, with a tiny float and strong preclinical survival data, making it a high-risk, high-reward opportunity.
ERNA's recent surge is attributed to its ability to achieve complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models, with some analysts initiating coverage and setting a price target of $30.

Generated by AI

News

Eterna Therapeutics appoints independent director Robert J. Spiegel

Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

Ernexa appoints Robert Spiegel to board of directors

12d agoInvesting.com

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the

12d agoYahoo Finance

Ernexa reports preclinical data for ERNA-201, refocuses on oncology

14d agoInvesting.com

Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment

15d agoYahoo Finance

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes

1mo agoYahoo Finance

Also Discussed

Investors talking about ERNA also mention

#	Name	Attention
1	RHE - Regional Health Properties, Inc.	——
2	Innsuites Hospitality TrustIHT	0%new
3	VERY - Vericity, Inc.	——
4	AIH - Aesthetic Medical International Holdings Group Limited	——
5	Willamette Valley Vineyards Inc.WVVI	0%0
6	SSY - SunLink Health Systems, Inc.	——
7	Nemaura Medical Inc.NMRD	0%new
8	American Shared Hospital ServicesAMS	0%new
9	Scopus Biopharma Inc.SCPS	0%new
10	TIRX - Tian Ruixiang Holdings Ltd	——

Ernexa Therapeutics Inc.

Healthcare
Biotechnology

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases. The company’s current programs center on engineered induced pluripotent stem cells and induced mesenchymal stem cells designed to create off-the-shelf, allogeneic treatments that can be manufactured without patient-specific cell harvesting. Its pipeline includes preclinical product candidates aimed at ovarian cancer and rheumatoid arthritis, reflecting its emphasis on therapeutic areas with high unmet medical need. Ernexa Therapeutics Inc. works at the intersection of cell engineering, immunology, and regenerative medicine, using proprietary mRNA and gene-modification technologies to direct how cells behave and deliver targeted biological effects. Headquartered in Cambridge, Massachusetts, the company operates as a clinical-stage biotechnology developer with a focused role in the evolving market for next-generation cellular medicines.

Website

Location

1035 Cambridge Street

Cambridge, MA, 02141

United States

Social

What share of all stock conversation is about ERNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 15

Ernexa Therapeutics reports positive preclinical data for ERNA-201, reinforcing its iMSC platform and accelerating oncology strategy.
The company has paused additional preclinical development expenditures on ERNA-201, preserving the program while concentrating on ERNA-101 and expanding its oncology pipeline.
ERNA-201 results provide a foundation for potential future advancement, and the company believes the data demonstrate proof-of-concept, making it a priority for future development.

Generated by AI

Sentiment

Of the messages about ERNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	54.55% -38.79	90.04% +7.12
Bearish	—	—	45.45% +38.79	9.96% -7.12

Bullish· Jul 15

ERNA-101 has shown complete tumor clearance and durable survival in ovarian cancer models, a significant development ahead of its planned clinical entry.
The stock has a low float of 668K, which can lead to rapid price movements.
The company's potential to easily 100x its current value has been highlighted, indicating a high potential for growth.

Bearish· Jul 15

The company's ovarian cancer treatment results were promising, but the stock has a history of fading after gap-up days, which may lead to a decline.
The stock has been a short signal since the market open, and shorts are likely to continue attacking the company.
The stock's price has been declining, and many investors are expecting it to drop below $8, with some even calling it a "bag trap".

Generated by AI

Topics

Of the messages about ERNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	2.03%
Technical Analysis	—	—	0%	1.92%
Analysts	—	—	0%	1.84%
Controversies	—	—	0%	0.01%
Earnings	—	—	0%	0.02%
Macro	—	—	0%	94.18%

Announcements· Oct 29

Eterna Therapeutics Inc. (ERNA) has partnered with Cellipont Bioservices to advance ERNA-101, an allogeneic iMSC-based cell therapy for ovarian cancer, into clinical manufacturing.
The collaboration will support current Good Manufacturing Practice (cGMP) process development and process scale-up for ERNA-101, which is designed as an off-the-shelf treatment for ovarian cancer.
ERNA-101 has shown potential in reprogramming "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth.

Technical Analysis· Oct 29

The $ERNA stock price is expected to break out above $2.40, with a potential target of $3 or higher if it can close above $2.50.
The stock has a support level at $1.76 and a resistance level at $2.38, with a potential target of $2.57 if it can close above $1.76.
The stock has a strong gap up above the 100-day EMA, with high volume, and is expected to consolidate and possibly flag above the $1.75 area.

Generated by AI

Community

Of the messages about ERNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	11.9%	7.16%
Newcomers	—	—	88.1%	92.84%

May 7

Newcomers are excited about ERNA's potential due to its strong preclinical survival data and ovarian cancer treatment candidate status, with some comparing it to multibaggers.
There is a high-volatility microfloat setup, with a tiny float and strong preclinical survival data, making it a high-risk, high-reward opportunity.
ERNA's recent surge is attributed to its ability to achieve complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models, with some analysts initiating coverage and setting a price target of $30.

Generated by AI

Ernexa Therapeutics

Social

Sep 15

Bullish· Jul 15

Bearish· Jul 15

Announcements· Oct 29

Technical Analysis· Oct 29

May 7

Eterna Therapeutics appoints independent director Robert J. Spiegel

Ernexa appoints Robert Spiegel to board of directors

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Ernexa reports preclinical data for ERNA-201, refocuses on oncology

Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Also Discussed

Ernexa Therapeutics Inc.

Company Information

Location

Eterna Therapeutics appoints independent director Robert J. Spiegel

Ernexa appoints Robert Spiegel to board of directors

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Ernexa reports preclinical data for ERNA-201, refocuses on oncology

Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Also Discussed

Social

Sep 15

Bullish· Jul 15

Bearish· Jul 15

Announcements· Oct 29

Technical Analysis· Oct 29

May 7